Neos Therapeutics at UBS Global Healthcare Conference (Replay)
05/23/17 at 3:00 p.m. ET
Corporate ProfileNeos Therapeutics is focused on developing, manufacturing and commercializing branded products utilizing our proprietary extended-release drug delivery technology platform. We have used this technology to develop our three product candidates being investigated for the treatment of attention deficit hyperactivity disorder, or ADHD. Our ADHD product candidates are extended-release, or XR, medications in patient-friendly, orally disintegrating tablets, or ODT, or liquid suspension dosage forms.
- 05/16/17Neos Therapeutics to Present at 2017 UBS Global Healthcare Conference
- 05/09/17Neos Therapeutics Reports First Quarter 2017 Financial Results
- 05/02/17Neos Therapeutics to Host First Quarter 2017 Financial Results Conference Call on May 9, 2017
- 03/14/17Neos Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results